Janney Montgomery Scott LLC Decreases Stake in Health Catalyst, Inc. (NASDAQ:HCAT)

Janney Montgomery Scott LLC reduced its stake in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 55.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,496 shares of the company's stock after selling 60,744 shares during the period. Janney Montgomery Scott LLC owned about 0.08% of Health Catalyst worth $350,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Quest Partners LLC purchased a new position in Health Catalyst in the 3rd quarter worth approximately $34,000. nVerses Capital LLC purchased a new position in Health Catalyst in the 3rd quarter worth approximately $59,000. Quadrature Capital Ltd purchased a new position in Health Catalyst in the 3rd quarter worth approximately $84,000. Harbor Capital Advisors Inc. increased its stake in Health Catalyst by 21.3% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company's stock worth $96,000 after purchasing an additional 2,064 shares during the period. Finally, Intech Investment Management LLC bought a new stake in shares of Health Catalyst in the 3rd quarter worth approximately $145,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Stock Down 2.3 %

Shares of NASDAQ HCAT traded down $0.13 during mid-day trading on Friday, hitting $5.42. 645,369 shares of the stock traded hands, compared to its average volume of 780,482. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst, Inc. has a 52 week low of $5.32 and a 52 week high of $10.14. The company has a market cap of $329.81 million, a price-to-earnings ratio of -4.01 and a beta of 1.34. The stock has a fifty day moving average price of $6.58 and a 200-day moving average price of $7.36.

Insiders Place Their Bets

In other Health Catalyst news, insider Linda Llewelyn sold 6,442 shares of the business's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $5.80, for a total value of $37,363.60. Following the sale, the insider now directly owns 92,260 shares of the company's stock, valued at approximately $535,108. The trade was a 6.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Daniel Lesueur sold 5,209 shares of the business's stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $5.76, for a total value of $30,003.84. Following the completion of the sale, the chief operating officer now directly owns 86,044 shares in the company, valued at $495,613.44. This trade represents a 5.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 81,169 shares of company stock valued at $629,068. 2.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. KeyCorp upgraded Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective on the stock in a research report on Wednesday, January 8th. Citigroup cut their price objective on Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a research report on Friday, January 10th. Canaccord Genuity Group cut their price objective on Health Catalyst from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, January 21st. Piper Sandler cut their price objective on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a research report on Tuesday. Finally, Wells Fargo & Company cut their price objective on Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 21st. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $10.20.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.